Huntington Disease
Amarin Announces Completion of Comprehensive Data Analysis From Phase III Huntington's Disease Program
Published in Medical Letter on the CDC and FDA, December 9th, 2007
Amarin Corporation plc (NASDAQ: AMRN) ("Amarin" or "Company") announced that management has met with the U.S. Food and Drug Administration (FDA) following the completion of a comprehensive data review from its large-scale Phase III studies of Miraxion to treat Huntington's disease (HD). The FDA indicated that one additional Phase III trial demonstrating robust results, in conjunction with the confirmatory evidence from the existing clinical data, may be sufficient clinical data to support a New Drug Application.
Rick Stewart, Chief Executive Officer of Amarin, commented "We are pleased with the results of the comprehensive clinical data review and are encouraged by the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- West Nile Virus
Earlier bites by uninfected mosquitoes boost West Nile deaths in lab mice - Clinical Trial Research
CytRx Reports Favorable Safety and Tolerability Results from High Dose, 28-Day Clinical Trial with Arimoclomol - Gastroenteritis
New Data Published in the Lancet Show GSK's ROTARIX(R) Offers Protection Against the Most Common Circulating Rotavirus Types - Keloid
Research on keloid published by W.G. Chernoff et al - Myeloma
Updated REVLIMID(R) (Lenalidomide) Plus Dexamethasone Data in Previously Treated Multiple Myeloma Reported in the New England Journal of Medicine - Pediatrics
InViragen Receives Funding From the Pediatric Dengue Vaccine Initiative - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
